Frontier Biotechnologies Inc
SSE:688221
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
F
|
Frontier Biotechnologies Inc
SSE:688221
|
8.5B CNY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
400.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
73.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.3B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Frontier Biotechnologies Inc
Glance View
Frontier Biotechnologies, Inc. engages in the research and development, production, and sale of medicines. The company is headquartered in Nanjing, Jiangsu and currently employs 495 full-time employees. The company went IPO on 2020-10-28. The firm's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The firm conducts its businesses within the China market and to overseas markets.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Frontier Biotechnologies Inc is -142.5%, which is above its 3-year median of -276%.
Over the last 3 years, Frontier Biotechnologies Inc’s Net Margin has increased from -679.3% to -142.5%. During this period, it reached a low of -679.3% on Mar 3, 2022 and a high of -142.5% on May 1, 2025.
